| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_48bfa223d5cdb05fcf652f5bb1461231 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2021-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b588c0608c7bd105d349f71d741830a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2af566289100747d90f46c754cfa01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33c774aef921e42b64fe5dcbb4cba40d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59c064bf7f819dab6df89ce2b4f8e8a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fff76c9321d7c31c898e6110f34e08d |
| publicationDate |
2021-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021161274-A1 |
| titleOfInvention |
Microrna angptl3 inhibitor |
| abstract |
The microRNA ANGPTL3 inhibitor includes methods of administering a miRNA capable of inhibiting ANGTPL3 and/or dyslipidemia to a subject in need thereof. The methods of administering the miRNA ANGPTL3 inhibitor may include administration of miRNA-181d to a subject in need thereof. The administration of miRNA-181d may inhibit ANGPTL3 activity, thereby reducing ANGPTL3's inhibition of lipoprotein lipase activity and increasing triglyceride degradation. The administration of miRNA-181d may be used to treat or prevent lipid metabolism disorders including dyslipidemia and dyslipidemia associated diseases, such as hyperlipidemia, atherosclerosis, heart disease, and the like. |
| priorityDate |
2020-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |